25001 | LACOSO | Lacosamide (LACO) | Vimpat | | 22724 | LDH-O | Lactate Dehydrogenase, Other Body Fluids | Body Fluid LDH | | 22811 | LDH | Lactate Dehydrogenase, Total | LD, LDH
| | 23146 | LACT-A | Lactate, Arterial | Lactic Acid (arterial), L-Lactate, LA
| | 25605 | LACA0H | Lactate, Arterial, 0 Hr, Sepsis | Lactic Acid (arterial), L-Lactate, LA, Sepsis, Protocol
| | 22812 | LAC-CSF | Lactate, CSF | Lactic Acid, CSF, L-Lactate, CSF | | 22722 | LACT | Lactate, Venous | Lactic Acid, Venous, L-Lactate, LA
| | 25604 | LACV0H | Lactate, Venous, 0 Hr, Sepsis | Lactic Acid, Venous, L-Lactate, LA, Sepsis, Protocol
| | 24971 | FLACTSO | Lactoferrin, Fecal, Quantitative (123016) | Fecal LactoferrinFecal Leukocytes IBD-Scan®
Stool Lactoferrin | The quantitative measurement of fecal lactoferrin released from leukocytes. | 22813 | LTT | Lactose Tolerance | LTT
| | 22814 | LAMO | Lamotrigine | Lamictal
| | 22817 | LDL-D | LDL Cholesterol, Direct | Lipoprotein, LDL - Direct, Cholesterol, LDL - Direct, Direct LDL | | 22822 | LEADUSO | Lead, 24 Hour, Urine (PBU) | Lead (Pb), Pb (Lead) Lead, Urine (PBU) U LEADUSO | | 22819 | BL | Lead, Blood | Pb, Lead in blood
| | 22820 | CBL | Lead, Capillary Blood | Pb - capillary, Lead in blood - capillary | | 22823 | LEGABSO | Legionella Antibody Panel (SLEG) | LDA (Legionnaires' Disease Antibody), Legionnaire's Disease | | 22824 | LEG-AG | Legionella Antigen, Urine | | | 26440 | LEGISO | Legionella Culture, Varies (LEGI) | Legionella Culture (LEGI), 50008-LEGI | | 25047 | LEGPSO | Legionella species, PCR (LEGRP) | Fluoribacter bozemanae Fluoribacter dumoffii Legionella Legionella sp Legionella spp Legionella bozemanae Legionella dumoffii Legionella gormanii Legionella hackeliae Legionella jordanis Legionella longbeachae Legionella micdadei Legionella oakridgensis Legionella pneumophila Legionella wadsworthii Legionellosis Legionnaires disease | | 25103 | LEPTNSO | Leptin (500716) | | | 25642 | LEPDTSO | Leptospira, IgM, Serum (LEPDT) | L. biflexa, Leptospirosis
| | 24887 | LEVE | Levetiracetam, Serum | Keppra, Leviteracetam | | 22827 | LID | Lidocaine, Serum | Xylocaine | | 26089 | LIDOSO | Lidocaine, Serum (LID) | Lidocaine (Xylocaine) | | 26391 | LINSSO | Linseed, IgE, Serum (LINS) | Flaxseed, Lium usitatissimum, Linseed, IgE, Serum (LINS)
| | 22829 | LIP | Lipase | | | 22828 | LIP-O | Lipase, Other Body Fluid | Body Fluid Lipase | | 26123 | LIPA1SO | Lipoprotein (a), Serum (LIPA1) | Lipoprotein (a), S Lipoprotein a Lp(a) apoprotein LP "little-A" | | 22831 | HDLTC | Lipoprotein Cholesterol and HDL | Cholesterol, Total and HDL, HDL Cholesterol and Total Cholesterol
| Includes total cholesterol, HDL-cholesterol, and calculated non-HDL cholesterol. | 23101 | LIPOB | Lipoprotein Panel, No LDL | | Includes Total Cholesterol, HDL Cholesterol, and Triglyceride. | 22832 | LIPOC | Lipoprotein Panel, With LDL | Lipo, Lipid Profile, Fasting Lipid Profile
| This panel includes measured Total Cholesterol, HDL Cholesterol, and Triglycerides. It also includes calculations for LDL Cholesterol and non-HDL Cholesterol. | 22834 | LI | Lithium | Li
| | 22835 | LIVER | Liver Panel | Hepatic Function Panel
| Albumin, Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Conjugated Bilirubin, Total Bilirubin, and Total Protein | 26629 | LKMSO | Liver/Kidney Microsome Type 1 Antibodies, Serum | Antibodies to Liver\Kidney Microsome Type 1, Serum; LKM1 (liver/kidney microsome type 1) antibodies; Microsomal (Liver/Kidney) Type 1 Antibodies; aLKM 1
| | 22836 | MISC | Lorazepam (64) | Ativan® | | 26401 | FUSFSO | Low-Grade Fibromyxoid Sarcoma (LGFMS), 16p11.2 (FUS or TLS) Rearrangement, FISH, Tissue (FUSF) | | TESTING ALGORITHM: This test does not include a pathology consult. If a pathology consultation is requested, PATHC / Pathology Consultation should be ordered and the appropriate FISH test will be ordered and performed at an additional charge. This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results. Additional charges will be incurred for application of all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred. | 22837 | MISC | LSD Screen, Urine (071159) | Lysergic Acid Diethylamide | | 22841 | LAPAN | Lupus Anticoagulant Panel | Lupus Inhibitor Work-up, Lupus Inhibitor Panel | Dilute Russell Viper Venom Time (DRVVT), Silica Clotting Time (SCT) | 22842 | LH | Luteinizing Hormone (LH) | | | 26223 | LHPEDSO | Luteinizing Hormone (LH), Pediatrics, Serum (LHPED) | Third Generation LH assay Ultrasensitive LH assay Lutropin | | 26063 | LNBABSO | Lyme CNS Infection, IgG with Antibody Index Reflex, Serum and Spinal Fluid (LNBAB) | Neuroinvasive Lyme Disease, Neuroborreliosis, Lyme Disease in the Central Nervous System, Lyme CNS Disease, C/S LBABSO | Lyme CNS Infection IgG Screen, CSF Lyme CNS Infection IgG, S
Reflex test: Lyme CNS Infection, IgG Ab Index This test begins with IgG screening of the spinal fluid (CSF) specimen. If the screen is negative, no additional testing will be performed. If the screen is positive, the paired CSF and serum specimens will be used to establish the antibody index. In order to establish the antibody index, the paired serum and CSF samples (collected within 24 hours of each other) are tested on the same run using quantitative assays to determine levels for the following analytes: 1. Anti-Borrelia species IgG levels in CSF and serum 2. Total IgG in CSF and serum 3. Albumin in CSF and serum These additional tests are necessary in order to normalize the level of anti-Borrelia antibodies to total IgG and albumin in the CSF and establish the antibody index ratio of anti-Borrelia antibodies in CSF-to-serum. This testing is performed at an additional charge. | 25226 | LYMPAN | Lyme Disease Serology, Serum | Lyme Disease, Borrelia burgdorferi, Lyme IgG and IgM, LYMSCR
| A chemiluminescence immunoassay screen test will be performed on all specimens. All specimens with a positive or equivocal screening result will reflex to Lyme Confirmatory Immunoassay, IgM and IgG. No confirmatory analysis will be performed on samples with a negative screening result.
| 26620 | PBORBSO | Lyme Disease, Molecular Detection, PCR, Blood (PBORB) | Borrelia burgdorferi by PCR; Lyme Disease (PCR); PCR; Tick-Borne Diseases; Spirochetes; Borrelia burgdorferi; Lyme Disease; Sensu lato genogroup; Borrelia garinii; Borrelia afzelii; Borrelia mayonii; Borrelia burgdorferi sensu lato genogroup
| B. burgdorferi, B. mayonii, B. garinii/B. afzelii
| 26589 | MISC | Lyme Disease, Molecular Detection, PCR, Varies (LYMPV) | Borrelia afzelii; Borrelia burgdorferi by PCR; Borrelia burgdorferi sensu lato genogroup; Borrelia garini;
Borrelia mayonii; Lyme Disease; Lyme Disease (PCR); Lyme Disease,CSF; PCR; Sensu lato group; Spirochetes; Tick-Borne Diseases | Previous serology positivity for Borrelia burgdorferi, is a requirement to order this test. All CSF and synovial fluid specimens MUST be approved by Dr. Taylor Wahlig or Dr. Sophie Arbefeville prior to sending to Mayo Clinic Labs.
B. burgdorferi PCR, B. mayonii PCR, B. garinii/B. afzelii PCR
| 26526 | LYMG | Lyme Immunoassay, IgM and IgG | Lyme confirmation, Lyme IgM, Lyme IgG, B. burgdorferi
| IgM and IgG-class antibodies to B. burgdorferi (Lyme disease)
| 25227 | LYIBM | Lyme Immunoblot, IgM | Lyme Immunoblot, IgM, Lyme Western Blot, IgM (LYBL-M)
| | 26274 | LPAGFSO | Lymphocyte Proliferation to Antigens, Blood (LPAGF) | Blastogenesis Antigens Immune Competence Lymphocyte Blastogenesis Antigen Lymphocyte Phytohemagglutiin Lymphocyte Transformation | If insufficient peripheral blood mononuclear cells (PBMCs) are isolated from the patient's sample due to low WBC counts or specimen volume received, selected dilutions or stimulants may not be tested at the discretion of the laboratory to ensure the most reliable results. Testing with 1 stimulant will always be performed. When adequate specimen is available for both stimulants to be tested, an additional test ID will be reflexed and billed separately. | 26454 | LPMGFSO | Lymphocyte Proliferation to Mitogens, Blood (LPMGF) | (PHA) Phytohemagglutinin Blastogenesis Mitogens Immune Competence In vitro T-Cell Function Lymphocyte Blastogenesis Mitogens Lymphocyte Transformation Mitogen Studies Mitogens Phytohemagglutinin (PHA) Pokeweed (PWM) PWM (Pokeweed) | Reflex Tests: Additional Flow Stimulant, LPMGF (MGSTM) Testing Algorithm: If insufficient peripheral blood mononuclear cells (PBMC) are isolated from the patient's sample due to low white blood cell counts or specimen volume received, selected dilutions or stimulants may not be tested at the discretion of the laboratory to ensure the most reliable results. Testing with one stimulant will always be performed. When adequate specimen is available for both stimulants to be tested, an additional test ID will be performed at an additional charge. | 25231 | HMISC | Lynch Syndrome DNA Mismatch Repair Proteins by IHC | Lynch Syndrome, Immunohistochemistry, IHC, DNA, HNPCC, Microsatellite Instability (MSI), Mismatch Repair Proteins, MMRP, hMLH-1, hMSH-2, hMSH-6, PMS2, Surgical and Histology. | hMLH-1, hMSH-2, hMSH-6, and PMS2 | 26216 | LSDSMSO | Lysosomal Storage Disorders Screen, Random, Urine (LSDS) | Alpha-Fucosidosis, Alpha-Galactosidase Deficiency, Alpha-Mannosidosis, Alpha-N-Acetylgalactosaminidase Deficiency, Arylsulfatase A Deficiency, Arylsulfatase B Deficiency, Aspartylglucosaminuria, Aspartylglycosaminuria, Beta-Galactosidase Deficiency, Beta-Glucuronidase Deficiency, Ceramide Hexosides, Ceramide Trihexosidase, Ceramide Trihexosidase Deficiency, Chondroitin-6-sulfate, Chondroitin-6 sulfate, Dermatan Sulfate, Diffuse Angiokeratoma, Fabry Disease, Fabry's Disease, GAGS (Glycosaminoglycans), Galactose-6-Sulfatase Deficiency, Galactosialidosis, GB3, GL3, Globotriaosylceramide, Glycosaminoglycans (GAGS), GM1 gangliosidosis, GM2 gangliosidosis, Heparan Sulfate, Hunter Syndrome, Hurler Syndrome, Hurler-Scheie Syndrome, I-Cell Disease, Iduronate Sulfatase Deficiency, Iduronidase Deficiency, Keratan Sulfate, LSD, Lysosomal Storage, Lysosomal Storage Disease, Maroteaux Lamy Syndrome, Maroteaux-Lamy Syndrome, Metachromatic Leukodystrophy, Morquio A, Morquio B, MPS I, MPS II, MPS III, MPS IVA, MPS IVB, MPS VI, MPS VII, Mucolipidosis II, Mucolipidosis III, Mucopolysaccharides, Mucopolysaccharidosis, Multiple Sulfatase Deficiency, Oligosaccharides, Oligosaccharidosis, Pompe Disease, Pseudo-Hurler Polydystrophy, Sandhoff Disease, Sanfilippo Syndrome, Scheie Syndrome, Schindler Disease, Sialidosis, Sly Syndrome, Sphingolipids, Sulfatides | This is a general urine screening test for a broad array of lysosomal storage (LSD) and related disorders. Not all LSDs are detectable by this method. Highlights: The first step in a diagnostic workup of an individual suspected of having a lysosomal storage disorder (LSD) includes urine analyses for metabolites associated with mucopolysaccharidoses, oligosaccharidoses, disorders of sulfatide degradation, and LSDs with characteristic urine profiles. This test contains a combined analysis of ceramide trihexosides, mucopolysaccharides, oligosaccharides, and sulfatides. This combined analysis of these disease-specific markers allows for the identification of disorders that may not be picked up using any of the single tests alone. | 22684 | MURASO | Lysozyme (Muramidase), Plasma (MURA) | Muramidase
| |
|